Accelerating Parkinson's Disease drug development with federated learning approaches

Amit Khanna¹, Jamie Adams², Chrystalina Antoniades³, Bastiaan R Bloem⁴, Camille Carroll⁵, Jesse Cedarbaum⁶, Joshua Cosman⁷, David T Dexter⁸, Marissa F Dockendorf⁹, Jeremy Edgerton¹⁰, Laura Gaetano¹, Erkuden Goikoetxea¹¹, Derek Hill¹², Fay Horak¹³, Elena S Izmailova¹⁴, Tairmae Kangarloo¹⁵, Dina Katabi¹⁶, Catherine Kopil¹⁷, Michael Lindemann¹⁸, Jennifer Mammen¹⁹, Kenneth Marek²⁰, Kevin McFarthing²¹, Anat Mirelman²², Martijn Muller²³, Gennaro Pagano²⁴, M Judith Peterschmitt²⁵, Jie Ren⁹, Lynn Rochester⁵, Sakshi Sardar²³, Andrew Siderowf²⁶, Tanya Simuni²⁷, Diane Stephenson²³, Christine Swanson-Fischer²⁸, John A Wagner¹⁴, Graham B Jones^{29

30}

Affiliations

¹ Neuroscience Development, Novartis AG, Basel, Switzerland.
² Department of Neurology and Center for Health and Technology, University of Rochester, Rochester, NY, USA.
³ NeuroMetrology Lab, University of Oxford, Oxford, UK.
⁴ Radboud University Medical Centre, Nijmegen, The Netherlands.
⁵ Translational and Clinical Research Institute, Newcastle University, Newcastle-upon-Tyne, UK.
⁶ Department of Neurology, Yale School of Medicine, New Haven, CT, 06511, USA.
⁷ AbbVie Pharmaceuticals, North Chicago, IL, USA.
⁸ Parkinson's UK, 50 Broadway, London, UK.
⁹ Merck & Co., Inc., Rahway, NJ, USA.
¹⁰ Biogen Inc, Cambridge, MA, USA.
¹¹ UCB Pharmaceuticals, Leuven, Belgium.
¹² Panoramic Digital Health, Grenoble, France.
¹³ Oregon Health and Science University, Portland, USA.
¹⁴ Koneksa Health, One World Trade Center, 285 Fulton St., New York, NY, USA.
¹⁵ Takeda Pharmaceuticals, Cambridge, MA, USA.
¹⁶ Department of Electrical Engineering and Computer Science, Massachusetts Institute of Technology, Cambridge, MA, USA.
¹⁷ The Michael J. Fox Foundation for Parkinson's Research, New York, NY, USA.
¹⁸ F. Hoffmann-La Roche Ltd, Basel, Switzerland.
¹⁹ University of Massachusetts, Dartmouth, College of Nursing and Health Sciences, Dartmouth, USA.
²⁰ Institute for Neurodegenerative Disorders, New Haven, CT, USA.
²¹ Parkinson's research advocate, Oxford, UK.
²² Faculty of Medicine and Sagol School of Neuroscience, Tel Aviv University and Tel Aviv Medical Center, Tel Aviv-Yafo, Israel.
²³ Critical Path Institute for Parkinson's Disease Consortium, Critical Path Institute, 1840 E River Rd, Suite 100, Tucson, AZ, 85718, USA.
²⁴ F. Hoffmann-La Roche, Basel, Switzerland.
²⁵ Research and Development, Sanofi, Cambridge, MA, USA.
²⁶ University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
²⁷ Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
²⁸ National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA.
²⁹ Data, Design and Clinical Innovation, Novartis Pharmaceuticals, Cambridge, MA, USA. graham.jones@novartis.com.
³⁰ Tufts University Medical Center, Boston, MA, USA. graham.jones@novartis.com.

PMID: 39567515
PMCID: PMC11579312
DOI: 10.1038/s41531-024-00837-5

Review

Accelerating Parkinson's Disease drug development with federated learning approaches

Amit Khanna et al. NPJ Parkinsons Dis. 2024.

. 2024 Nov 21;10(1):225.

doi: 10.1038/s41531-024-00837-5.

Authors

Affiliations

¹ Neuroscience Development, Novartis AG, Basel, Switzerland.
² Department of Neurology and Center for Health and Technology, University of Rochester, Rochester, NY, USA.
³ NeuroMetrology Lab, University of Oxford, Oxford, UK.
⁴ Radboud University Medical Centre, Nijmegen, The Netherlands.
⁵ Translational and Clinical Research Institute, Newcastle University, Newcastle-upon-Tyne, UK.
⁶ Department of Neurology, Yale School of Medicine, New Haven, CT, 06511, USA.
⁷ AbbVie Pharmaceuticals, North Chicago, IL, USA.
⁸ Parkinson's UK, 50 Broadway, London, UK.
⁹ Merck & Co., Inc., Rahway, NJ, USA.
¹⁰ Biogen Inc, Cambridge, MA, USA.
¹¹ UCB Pharmaceuticals, Leuven, Belgium.
¹² Panoramic Digital Health, Grenoble, France.
¹³ Oregon Health and Science University, Portland, USA.
¹⁴ Koneksa Health, One World Trade Center, 285 Fulton St., New York, NY, USA.
¹⁵ Takeda Pharmaceuticals, Cambridge, MA, USA.
¹⁶ Department of Electrical Engineering and Computer Science, Massachusetts Institute of Technology, Cambridge, MA, USA.
¹⁷ The Michael J. Fox Foundation for Parkinson's Research, New York, NY, USA.
¹⁸ F. Hoffmann-La Roche Ltd, Basel, Switzerland.
¹⁹ University of Massachusetts, Dartmouth, College of Nursing and Health Sciences, Dartmouth, USA.
²⁰ Institute for Neurodegenerative Disorders, New Haven, CT, USA.
²¹ Parkinson's research advocate, Oxford, UK.
²² Faculty of Medicine and Sagol School of Neuroscience, Tel Aviv University and Tel Aviv Medical Center, Tel Aviv-Yafo, Israel.
²³ Critical Path Institute for Parkinson's Disease Consortium, Critical Path Institute, 1840 E River Rd, Suite 100, Tucson, AZ, 85718, USA.
²⁴ F. Hoffmann-La Roche, Basel, Switzerland.
²⁵ Research and Development, Sanofi, Cambridge, MA, USA.
²⁶ University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
²⁷ Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
²⁸ National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA.
²⁹ Data, Design and Clinical Innovation, Novartis Pharmaceuticals, Cambridge, MA, USA. graham.jones@novartis.com.
³⁰ Tufts University Medical Center, Boston, MA, USA. graham.jones@novartis.com.

PMID: 39567515
PMCID: PMC11579312
DOI: 10.1038/s41531-024-00837-5

Abstract

Parkinson's Disease is a progressive neurodegenerative disorder afflicting almost 12 million people. Increased understanding of its complex and heterogenous disease pathology, etiology and symptom manifestations has resulted in the need to design, capture and interrogate substantial clinical datasets. Herein we advocate how advances in the deployment of artificial intelligence models for Federated Data Analysis and Federated Learning can help spearhead coordinated and sustainable approaches to address this grand challenge.

PubMed Disclaimer

Conflict of interest statement

Competing interests: AK, LG and GJ are all employees of Novartis Pharmaceuticals and may hold common stock in the company. MD and JR are employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, and may own stock and/or stock options. JA has received research support from the Michael J. Fox Foundation for Parkinson’s Research, NIH/NINDS, the Huntington Study Group, and PhotoPharmics; received compensation as a consultant/steering committee/advisory board member from the Huntington Study Group, the Parkinson Study Group, Sana Biotechnology, Biohaven, and the Michael J. Fox Foundation for Parkinson’s Research. CA is supported by the National Institute for Health Research Oxford Biomedical Research Centre and received research grant support from UCB Pharma, MSD, EPSRC and has been a consultant for UCB and J & J. BRB: No declaration. CC has been a consultant for AbbVie, Mission Therapeutics and Roche and received research funding from Parkinson’s UK, Edmond J Safra Foundation, National Institute of Health and Care Research and Cure Parkinson’s. JCe has been a consultant for VanquaBio, MiCure, Elsie Bio, has stock/options from Vanqua Bio, Micure, Immunobrain Checkpoint and has received grant funding from ASAP, the Marcus Foundation. JCo is an employee of AbbVie Pharmaceuticals. DTD: No declaration. JE is an employee of Biogen. EG is an employee of UCB Pharmaceuticals. DH has been a consultant for the Critical Path Institute, a share holder and employee of Panoramic Digital Health and received funding from the EPSRC, and France Relance. FH is employed part-time at Clario. ESI is an employee of Koneksa Health and may own company stock. TK is an employee of Takeda Pharmaceuticals. DK No declaration. CK No declaration. ML is a consultant to F. Hoffmann– La Roche Ltd via Inovigate. JM has consulted for and received funding from the Michael J Fox Foundation for Parkinson’s Research. KM No declaration. KMc No declaration. AM has been a consult for Koneksa and received grant funding from MJFF, JPND, US Department of Defense, and the EU IMI. MM No declaration. GP is an employee of F. Hoffmann La-Roche. MJP is an employee of Sanofi, and may hold shares and/or stock options in the company. LR has received honorarium from the MJ Fox Foundation and grant funding from EU, NIHR, MRC, EPSRC, Cure Parkinson’s Trust, PDUK, Dunhill Medical Trust. SS No declaration. AS has been a consultant to the following companies in the past year: Acadia, Boerhinger-Ingelheim, GE Healthcare, Wave Life Sciences, Inhibikase, Prevail, Mitzubishi and Alertity Therapeutics. He has served on DSMBs for the Huntington Study Group and The Healey ALS Consortium (Massachusetts General Hospital).He has received grant funding from the Michael J. Fox Foundation, NIA and NINDS. TS has served as a consultant for AskBio, Amneal, Blue Rock Therapeutics, Critical Path for Parkinson’s Consortium (CPP), Denali, General Electric, Kyowa, Neuroderm/ MTPA, Prevail/ Lilly, Roche, Sanofi, Sinopia, Takeda and Vanqua Bio. She has served on the ad board for AskBio, Amneal, Biohaven, Denali, GAIN, General Electric, Kyowa, MJFF, Neuron23, Parkinson Study Group, Prevail/ Lilly, and Roche. She has also served as a member of the scientific advisory board of Koneksa, Neuroderm/ MTPA, Sanofi and UCB. Dr. Simuni has received research funding from Amneal, Biogen, Neuroderm, Prevail, Roche, UCB and is an investigator for NINDS, MJFF, Parkinson’s Foundation. DS No declaration. CS-F No declaration. JAW is an employee of Koneksa Health and may own stock and/or stock options. No funding is associated with the production of this manuscript.

Figures

**Fig. 1**
Diversity of clinical data from people with PD in the CPath database.

**Fig. 2**
Hypothetical Federated learning network composed of four partners with a fifth, nonprofit coordinating body overseeing aggregation and strategy.

See this image and copyright information in PMC

References

1. Schlander, M., Hernandez-Villafuerte, K., Cheng, C. Y., Mestre-Ferrandiz, J. & Baumann, M. How Much Does It Cost to Research and Develop a New Drug? A Systematic Review and Assessment. Pharmacoeconomics39, 1243–1269 (2021). - PMC - PubMed
1. Sun, D., Gao, W., Hu, H. & Zhou, S. Why 90% of clinical drug development fails and how to improve it? Acta Pharm. Sin. B.12, 3049–3062 (2022). - PMC - PubMed
1. Gribkoff, V. K. & Kaczmarek, L. K. The need for new approaches in CNS drug discovery: Why drugs have failed, and what can be done to improve outcomes. Neuropharmacology120, 11–19 (2017). - PMC - PubMed
1. Skaria, A. P. The Economic and Societal Burden of Alzheimer Disease: Managed Care Considerations. Am. J. Manag Care.28, S188–S196 (2022). - PubMed
1. Dorsey, E. R. & Bloem, B. R. The Parkinson Pandemic-A Call to Action. JAMA Neurol.75, 9–10 (2018). - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
- PubMed Central

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Accelerating Parkinson's Disease drug development with federated learning approaches

Affiliations

Accelerating Parkinson's Disease drug development with federated learning approaches

Authors

Affiliations

Abstract

Conflict of interest statement

Figures

References

Publication types

LinkOut - more resources

Full Text Sources